Big news is coming out on the Corona virus vaccine in India. The advance trial of the Corona vaccine developed by Oxford University in Britain will also start in the country. DGCI i.e. Controller General of India has approved the Serum Institute of India for its advance trial. Serum Institute will be able to start Phase II and Phase III vaccine trials in the country this month. It is known that Oxford University and AstraZeneca company together with Indian vaccine manufacturer Serum, are going to mass produce the vaccine.
Serum Institute, a leading vaccine manufacturer, will manufacture and launch this AZD1222 vaccine in India under the name Covishield. According to reports, this vaccine is to be supplied to more than 50 countries including India. However, according to CEO Adar Poonawala, 50 per cent of the total vaccines produced by the company will be for India.
1600 people will be tried in India
Based on preliminary information, it is being said that the trial of this vaccine in India will be on about 1600 people. According to a report by the Indian Express, the trial of the Serum Institute will take place in 18 places in the country. After the approval of DGCI, the work of preparing the vaccine will be expedited.
